

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

August 30, 2024

To Shareholders,

Company Name: Renaissance Inc.

Representative: Keisuke Furuta, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact Administration Dept.

**Announcement of the joint R&D collaboration agreement for artificial intelligence (AI)-based software as a medical device (SaMD) with Taipei Medical University (TMU)-Biotech Co., Ltd.**

We are pleased to announce that we have contracted the joint R&D collaboration agreement with Taipei Medical University (TMU)-Biotech Co., Ltd., a wholly owned subsidiary of Taipei Medical University (TMU), for the research, development and commercialization of artificial intelligence (AI)-based software as a medical device (SaMD).

Due to the amendment of the Japan Pharmaceutical and Medical Device Act in November 2014, computer programs (software) for the purpose of diagnosis and treatment have been newly positioned as medical devices, called software as a medical device (SaMD). Our company has built networks with many medical institutions and multiple medical fields in the process of conducting many investigator-initiated clinical trials, and has advantages such as easy access to medical issues and medical data (medical support), being able to conclude joint research business agreements with multiple IT companies, such as NEC, through open innovation (technical support), and being able to comply with pharmaceutical regulations in the process of conducting investigator-initiated clinical trials for pharmaceuticals. We are developing SaMDs that utilize AI to support diagnosis and treatment in several medical fields. The SaMD for respiratory function test diagnosis was licensed to Chest Co., Ltd. in July 2020, and clinical performance tests for SaMDs for diabetes mellitus and hemodialysis will be conducted in Japan this year for the regulatory approval.

TMU-Biotech is a wholly owned subsidiary of Taipei Medical University (TMU)(<https://eng.tmu.edu.tw>) to commercialize the medical seeds of TMU. This joint R&D agreement is for us and TMU to collaborate in commercializing the pipelines of AI-based SaMD both in Japan and Taiwan. TMU is a private medical university established in 1960, ranked at the top level in Taiwan, and has six affiliated hospitals total of 3,000 beds operating under the One-Campus unified health information system (HIS). The One-Campus HIS is operated by dedicated health information and data scientists, who will support the development of SaMD in the TMU ecosystem. Renaissance Inc. and TMU-Biotech will work together for the R&D of novel, innovative AI-based SaMDs to commercialize both in Taiwan and Japan, and to conduct clinical performance tests for the regulatory approval in both countries.